Nuvalent Inc (NUVL)
66.50
-2.07
(-3.02%)
USD |
NASDAQ |
May 08, 13:13
Nuvalent Cash from Operations (TTM): -99.74M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -99.74M |
September 30, 2023 | -87.31M |
June 30, 2023 | -82.50M |
March 31, 2023 | -75.84M |
December 31, 2022 | -64.97M |
September 30, 2022 | -60.15M |
June 30, 2022 | -53.37M |
Date | Value |
---|---|
March 31, 2022 | -47.61M |
December 31, 2021 | -40.00M |
September 30, 2021 | -31.98M |
June 30, 2021 | -24.65M |
March 31, 2021 | -17.89M |
December 31, 2020 | -14.95M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-99.74M
Minimum
Dec 2023
-14.95M
Maximum
Dec 2020
-53.92M
Average
-53.37M
Median
Jun 2022
Cash from Operations (TTM) Benchmarks
Geron Corp | -183.63M |
Verastem Inc | -86.46M |
Karyopharm Therapeutics Inc | -92.72M |
Syndax Pharmaceuticals Inc | -160.60M |
AnaptysBio Inc | -120.80M |